Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 10:30PM GMT
Release Date Price: R$19.23
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

Good afternoon. I'm Chris Schott from JPMorgan. And it's my pleasure to be hosting this session with Eli Lilly today. From Lilly, we have the company's Chairman and CEO, Dave Ricks.

Dave, thanks for joining us for the fireside again this year. It was obviously a very busy year for Lilly, again, in 2019. Seems like 2020 is setting up to be an important one for the company. Before we dig into this -- the specific topics on the fireside, do you want to make some opening remarks, and we'll...

David A. Ricks
Eli Lilly and Company - Chairman, CEO & President

Yes, absolutely. Thanks for having us again, and I want to thank my team here in the room. We had a strong year last year, and it's due to their hard work.

Maybe just to frame before we get into this, we just had our guidance call on December '19 for 2020. And it ends a period of remarkable progress for the company. As we exited a series of patent expiries in 2015, we set out a series of goals and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot